Posted by Michael Wonder on 15 Jun 2019
Blueprint Medicines submits new drug application to U.S. FDA for avapritinib for the treatment of PDGFRA exon 18 mutant GIST and fourth-line GIST
14 June 2019 - Blueprint Medicines Corporation today announced it has submitted a new drug application to the U.S. FDA for avapritinib for the treatment of adult patients with PDGFRA Exon 18 mutant gastro-intestinal stromal tumours (GIST), regardless of prior therapy, and fourth-line GIST.
Currently, no effective therapy exists for either population. Avapritinib is an investigational, potent and highly selective KIT and PDGFRA inhibitor for patients with advanced GIST.
Blueprint Medicines has requested priority review for the application, which, if granted, could result in a six-month review process.
